BNP Paribas Financial Markets Has $1.07 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

BNP Paribas Financial Markets raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 40.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 55,188 shares of the biotechnology company’s stock after purchasing an additional 15,784 shares during the period. BNP Paribas Financial Markets’ holdings in Arrowhead Pharmaceuticals were worth $1,069,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ARWR. Fifth Third Bancorp boosted its stake in Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 354 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $52,000. Meeder Asset Management Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after buying an additional 3,333 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after buying an additional 788 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $96,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ARWR. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 27th. Sanford C. Bernstein lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. HC Wainwright lifted their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Finally, Citigroup lowered their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.70.

Arrowhead Pharmaceuticals Trading Up 2.8 %

Arrowhead Pharmaceuticals stock opened at $23.92 on Wednesday. The stock has a market cap of $2.98 billion, a P/E ratio of -4.76 and a beta of 0.90. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $17.05 and a fifty-two week high of $39.83. The firm’s fifty day moving average price is $20.78 and its 200-day moving average price is $23.18. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.